Institut Pasteur, Unité d'Immunobiologie de l'Infection, Paris, France.
J Clin Invest. 2013 Apr;123(4):1501-12. doi: 10.1172/JCI66576. Epub 2013 Mar 15.
Mycolactone is a diffusible lipid secreted by the human pathogen Mycobacterium ulcerans, which induces the formation of open skin lesions referred to as Buruli ulcers. Here, we show that mycolactone operates by hijacking the Wiskott-Aldrich syndrome protein (WASP) family of actin-nucleating factors. By disrupting WASP autoinhibition, mycolactone leads to uncontrolled activation of ARP2/3-mediated assembly of actin in the cytoplasm. In epithelial cells, mycolactone-induced stimulation of ARP2/3 concentrated in the perinuclear region, resulting in defective cell adhesion and directional migration. In vivo injection of mycolactone into mouse ears consistently altered the junctional organization and stratification of keratinocytes, leading to epidermal thinning, followed by rupture. This degradation process was efficiently suppressed by coadministration of the N-WASP inhibitor wiskostatin. These results elucidate the molecular basis of mycolactone activity and provide a mechanism for Buruli ulcer pathogenesis. Our findings should allow for the rationale design of competitive inhibitors of mycolactone binding to N-WASP, with anti-Buruli ulcer therapeutic potential.
Mycolactone 是一种由人类病原体溃疡分枝杆菌分泌的可扩散脂质,可诱导形成开放性皮肤损伤,即布鲁里溃疡。在这里,我们表明,mycolactone 通过劫持沃氏综合征蛋白 (WASP) 家族的肌动蛋白成核因子来发挥作用。通过破坏 WASP 自身抑制,mycolactone 导致 ARP2/3 介导的肌动蛋白在细胞质中的组装不受控制地激活。在上皮细胞中,mycolactone 诱导的 ARP2/3 在核周区域集中,导致细胞黏附缺陷和定向迁移。体内将 mycolactone 注射到小鼠耳朵中,可一致改变角蛋白细胞的连接组织和分层,导致表皮变薄,随后破裂。用 N-WASP 抑制剂 wiskostatin 共同给药可有效抑制这种降解过程。这些结果阐明了 mycolactone 活性的分子基础,并为布鲁里溃疡发病机制提供了一种机制。我们的发现应该可以合理设计竞争性抑制剂,以抑制 mycolactone 与 N-WASP 的结合,从而具有抗布鲁里溃疡的治疗潜力。